Aflibercept With Versus Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic Changes From a Randomized Clinical Trial.
Kelvin Yc Teo, Noa Gilead, Zehua Jiang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of intravitreal aflibercept with or without reduced-fluence photodynamic therapy (PDT) on optical coherence tomography angiography (OCTA) changes in 55 treatment-naïve eyes with polypoidal choroidal vasculopathy (PCV) over 52 weeks. The study found that a greater reduction in branching neovascular network (BNN) vessel density at week 12 was associated with polypoidal lesion closure at week 52 (OR 0.62).
Key findings
- Total lesion area decreased at week 12 but returned toward baseline by week 52 in both treatment arms.
- BNN area decreased at week 12 and remained reduced at week 52 for both combination and monotherapy.
- BNN vessel density reduction was greater in the combination arm at week 12 (-10 ± 15% vs -3 ± 12%, P = .02).
- Greater reduction in BNN vessel density at week 12 was associated with polypoidal lesion closure at week 52 (OR 0.62, P = .03).
Why it matters
Understanding the relationship between OCTA-derived vascular changes and treatment response in PCV can help clinicians identify effective monitoring strategies and predict patient outcomes, potentially improving management of this condition.